Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simurosertib - Takeda Oncology

Next Previous
Search
Drug Profile

Simurosertib - Takeda Oncology

Alternative Names: cell division cycle 7 inhibitor TAK-931; TAK-931; TAK931F; ZL-2309

Latest Information Update: 25 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda Oncology
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Pyrazoles; Small molecules; Thienopyridines
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 Dec 2022 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands, Netherlands (PO)
  • 31 Dec 2022 Discontinued - Phase-II for Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in Japan, USA (PO)
  • 31 Dec 2022 Discontinued - Phase-II for Oesophageal cancer (Metastatic disease, Second-line therapy or greater) in Japan, USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top